Repertoire Partners’s Standard BioTools LAB Stock Holding History

Repertoire Partners’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100	Closed	-$193	–	17
2023 Q2	$193	Hold	100	–	–	﹤0.01%	13
2023 Q1	$195	Hold	100	–	–	﹤0.01%	32
2022 Q4	$117	Hold	100	–	–	﹤0.01%	49
2022 Q3	$0	Hold	100	–	–	﹤0.01%	68
2022 Q2	$0	Hold	100	–	–	﹤0.01%	88
2022 Q1	$0	Sell	100 -999,900	-100%	-$3.45M	﹤0.01%	53
2021 Q4	$3.92M	Buy	+1,000,000	New	+$4.68M	3.24%	11

Other funds holding LAB

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Repertoire Partners's LAB Position: Q3 2023 in Review

Repertoire Partners sold out of Standard BioTools (LAB) in Q3 2023, closing a stake of 100 shares — an estimated $193 sold.

Repertoire Partners first reported a position in LAB in Q4 2021 and held it in 7 quarters. The position peaked at $3.92M in Q4 2021. 72 funds tracked by Wall St. Rank hold LAB as of Q3 2023.

Repertoire Partners reported no remaining Standard BioTools position as of Q3 2023 after selling out during the quarter.
Repertoire Partners sold 100 Standard BioTools shares in Q3 2023, an estimated $193.
Repertoire Partners first reported a position in Standard BioTools in Q4 2021 and held it in 7 quarters.
Repertoire Partners's Standard BioTools position peaked at $3.92M in Q4 2021.
72 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2023.

Based on Repertoire Partners's 13F filing for Q3 2023, filed 14 Nov 2023.